Letter: the potential risk of HBV reactivation in patients with resolved HBV infection during direct-acting antiviral therapy

Aliment Pharmacol Ther. 2017 Oct;46(7):702-703. doi: 10.1111/apt.14227.

Authors

R Huang¹, J Wang², Y Hao³, X Yan¹, C Wu¹

Affiliations

¹ Department of Infectious Diseases, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, Jiangsu, China.
² Department of Infectious Diseases, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, Jiangsu, China.
³ Department of Intensive Care Unit, Nanjing Drum Tower Hospital, Nanjing University Medical School, Nanjing, Jiangsu, China.

PMID: 28880444
DOI: 10.1111/apt.14227

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't
Comment

MeSH terms

Antiviral Agents
Hepatitis B virus*
Hepatitis B*
Humans
Virus Activation / drug effects

Substances

Antiviral Agents